É. Sbidian

6.4k total citations · 2 hit papers
168 papers, 3.6k citations indexed

About

É. Sbidian is a scholar working on Immunology, Dermatology and Rheumatology. According to data from OpenAlex, É. Sbidian has authored 168 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Immunology, 48 papers in Dermatology and 39 papers in Rheumatology. Recurrent topics in É. Sbidian's work include Psoriasis: Treatment and Pathogenesis (59 papers), Dermatology and Skin Diseases (30 papers) and Health Systems, Economic Evaluations, Quality of Life (20 papers). É. Sbidian is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (59 papers), Dermatology and Skin Diseases (30 papers) and Health Systems, Economic Evaluations, Quality of Life (20 papers). É. Sbidian collaborates with scholars based in France, United Kingdom and Spain. É. Sbidian's co-authors include O. Chosidow, Laurence Le Cleach, Camille Hua, P. Wolkenstein, Carolyn Hughes, Anna Chaimani, Luigi Naldi, I. García‐Doval, Laëtitia Penso and Laura Pina Vegas and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Clinical Infectious Diseases.

In The Last Decade

É. Sbidian

156 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis

2017 334 citations É. Sbidian, Anna Chaimani et al. Cochrane Database of Systematic Reviews profile →
Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database

2022 99 citations Léa Hoisnard, Bénédicte Lebrun‐Vignes et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
É. Sbidian France	36	1.5k	1.2k	746	563	471	168	3.6k
Bernard Yu‐Hor Thong Singapore	34	915 0.6×	1.3k 1.1×	1.5k 2.0×	397 0.7×	300 0.6×	111	5.9k
Michael Bigby United States	30	1.2k 0.8×	1.1k 0.9×	410 0.5×	634 1.1×	471 1.0×	102	4.9k
R.J.G. Chalmers United Kingdom	29	1.5k 1.0×	1.1k 0.9×	691 0.9×	443 0.8×	468 1.0×	80	3.0k
Stefano Piaserico Italy	31	1.5k 1.0×	1.6k 1.3×	459 0.6×	295 0.5×	1.2k 2.5×	158	3.7k
Moisés Labrador‐Horrillo Spain	30	609 0.4×	709 0.6×	1.2k 1.7×	473 0.8×	1.1k 2.4×	123	3.0k
Fenglong Xie United States	38	882 0.6×	282 0.2×	2.1k 2.8×	323 0.6×	1.3k 2.7×	140	4.3k
Marian T. McEvoy United States	28	1.3k 0.8×	1.2k 1.0×	929 1.2×	496 0.9×	686 1.5×	75	3.2k
Anja Strangfeld Germany	28	976 0.6×	215 0.2×	2.5k 3.4×	385 0.7×	505 1.1×	136	3.8k
Marie‐Charlotte Brüggen Switzerland	23	944 0.6×	570 0.5×	441 0.6×	155 0.3×	422 0.9×	62	3.5k
Moshe Ben‐Shoshan Canada	35	450 0.3×	874 0.7×	711 1.0×	407 0.7×	140 0.3×	217	3.9k

Countries citing papers authored by É. Sbidian

Since Specialization

Citations

This map shows the geographic impact of É. Sbidian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by É. Sbidian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites É. Sbidian more than expected).

Fields of papers citing papers by É. Sbidian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by É. Sbidian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by É. Sbidian. The network helps show where É. Sbidian may publish in the future.

Co-authorship network of co-authors of É. Sbidian

This figure shows the co-authorship network connecting the top 25 collaborators of É. Sbidian. A scholar is included among the top collaborators of É. Sbidian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with É. Sbidian. É. Sbidian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Afach, Sivem, et al.. (2024). Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review. Journal of Clinical Epidemiology. 173. 111406–111406. 2 indexed citations

Descalzo, M.Á., Mahmoud Zureik, R. Rivera, et al.. (2024). Drug survival and safety of biosimilars for treating psoriasis compared with originator adalimumab: a multinational cohort study. British Journal of Dermatology. 192(4). 641–652. 1 indexed citations

Afach, Sivem, Antoine Meyer, Zenas Z N Yiu, et al.. (2024). Funding and conclusions of network meta-analyses on targeted therapies in inflammatory diseases: an overview. Journal of Clinical Epidemiology. 172. 111411–111411. 1 indexed citations

Sbidian, É., et al.. (2023). Reality of drug-induced erythema multiforme: A French pharmacovigilance study. Therapies. 78(6). 711–719. 1 indexed citations

Hoisnard, Léa, et al.. (2023). Validation of an Algorithm to Identify Epidermal Necrolysis on a Medico-Administrative Database. Journal of Investigative Dermatology. 144(3). 708–710.e7. 4 indexed citations

Cleach, Laurence Le, et al.. (2023). Long-term clinical trials of biologics in plaque psoriasis demonstrate heterogeneous study designs. British Journal of Dermatology. 188(5). 677–678. 2 indexed citations

Bergqvist, Christina, L. Fertitta, S. Ferkal, et al.. (2023). In-Hospital Clinical Features, Morbidity, and Mortality of Patients with Neurofibromatosis 1 in France: A Nationwide, Population-Based Retrospective Cohort Study. Journal of Investigative Dermatology. 143(12). 2408–2415.e7. 4 indexed citations

Zureik, Mahmoud, R. Rivera, Antonio Sahuquillo‐Torralba, et al.. (2023). Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study. BMJ Open. 13(7). e075197–e075197. 3 indexed citations

Mahé, E., M.‐A. Richard, Yann De Rycke, et al.. (2021). Impact de l’épidémie de COVID-19 lors de la 1ère vague sur les patients de la cohorte PSOBIOTEQ traités pour psoriasis cutané. PubMed Central. 1(8). A298–A299. 1 indexed citations

10.

Penso, Laëtitia, Viet-Thi Tran, Claire Hotz, et al.. (2021). Baseline Characteristics of a National French E-Cohort of Hidradenitis Suppurativa in ComPaRe and Comparison with Other Large Hidradenitis Suppurativa Cohorts. Dermatology. 237(5). 748–758. 5 indexed citations

11.

Hughes, Carolyn, et al.. (2020). Interventions for chronic palmoplantar pustulosis: abridged Cochrane systematic review and GRADE assessments. British Journal of Dermatology. 184(6). 1023–1032. 10 indexed citations

12.

Afach, Sivem, Canelle Mazaud, C. Phan, et al.. (2020). Quality and Reporting Completeness of Systematic Reviews and Meta-Analyses in Dermatology. Journal of Investigative Dermatology. 141(1). 64–71. 8 indexed citations

13.

Afach, Sivem, Anna Chaimani, Theodoros Evrenoglou, et al.. (2020). Meta‐analysis results do not reflect the real safety of biologics in psoriasis*. British Journal of Dermatology. 184(3). 415–424. 23 indexed citations

14.

Sbidian, É., Anna Chaimani, I. García‐Doval, et al.. (2020). Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database of Systematic Reviews. 1. CD011535–CD011535. 128 indexed citations

15.

Oger, Emmanuel, S. Buche, M. Delage, et al.. (2019). Concordance of severity scores for photographic assessment of hidradenitis suppurativa. British Journal of Dermatology. 182(2). 515–516.

16.

Phan, Carole, Khaled Ezzedine, Chester Lai, et al.. (2017). Agreement Between Self-reported Inflammatory Skin Disorders and Dermatologists’ Diagnosis: A Cross-sectional Diagnostic Study. Acta Dermato Venereologica. 97(10). 1243–1244. 15 indexed citations

17.

Gottlieb, J., S. Oro, M. Alexandre, et al.. (2016). Idiopathic linear IgA bullous dermatosis: prognostic factors based on a case series of 72 adults. British Journal of Dermatology. 177(1). 212–222. 34 indexed citations

18.

Méni, C., et al.. (2015). Treatment of Neurofibromas with a Carbon Dioxide Laser: A Retrospective Cross-Sectional Study of 106 Patients. Dermatology. 230(3). 263–268. 22 indexed citations

19.

Cros, Jérôme, É. Sbidian, Stéphane Hans, et al.. (2013). Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours. Annals of Oncology. 24(10). 2624–2629. 68 indexed citations

20.

Sbidian, É., S. Hadj‐Rabia, Vincent M. Riccardi, et al.. (2012). Clinical characteristics predicting internal neurofibromas in 357 children with neurofibromatosis-1: results from a cross-selectional study. Orphanet Journal of Rare Diseases. 7(1). 62–62. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact